Nephros Inc Cash Flow Conversion Efficiency
Nephros Inc cash flow conversion efficiency. Based on the latest financial reports, Nephros Inc (NEPH) has a cash flow conversion efficiency ratio of -0.156x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.67 Million) by net assets ($10.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nephros Inc (2002–2025)
Cash flow conversion efficiency of Nephros Inc from 2002 to 2025. This chart illustrates how Nephros Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Nephros Inc stock quote for real-time trading data and today's change.
Nephros Inc Cash Flow Conversion Ratio Explained
Nephros Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nephros Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nephros Inc ranked by their cash flow conversion efficiency. Also see Nephros Inc (NEPH) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pancontinental Energy NL
AU:PCL
|
-0.064x |
|
Aldeyra The
NASDAQ:ALDX
|
-0.121x |
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
0.267x |
|
Haesung Optics Co. Ltd
KQ:076610
|
-0.009x |
|
Mabion S.A.
WAR:MAB
|
-0.268x |
|
GeneFerm Biotechnology Co Ltd
TWO:1796
|
0.002x |
|
Reino Capital SA
WAR:RNC
|
0.064x |
|
Jack Chia Industries (Thailand) Public Company Limited
BK:JCT
|
0.021x |
Annual Cash Flow Conversion Efficiency for Nephros Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Nephros Inc from 2002 to 2025. Review NEPH FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.20 Million | $1.65 Million | 0.161x | +381.36% |
| 2024-12-31 | $8.59 Million | $-492.00K | -0.057x | -157.92% |
| 2023-12-31 | $8.36 Million | $827.00K | 0.099x | +127.17% |
| 2022-12-31 | $8.88 Million | $-3.23 Million | -0.364x | -279.03% |
| 2021-12-31 | $14.75 Million | $-1.42 Million | -0.096x | +78.33% |
| 2020-12-31 | $15.57 Million | $-6.90 Million | -0.443x | -49.75% |
| 2019-12-31 | $7.69 Million | $-2.28 Million | -0.296x | +45.05% |
| 2018-12-31 | $6.80 Million | $-3.66 Million | -0.539x | -1264.21% |
| 2017-12-31 | $1.95 Million | $-77.00K | -0.039x | +98.75% |
| 2016-12-31 | $667.00K | $-2.11 Million | -3.166x | -121.11% |
| 2015-12-31 | $2.66 Million | $-3.81 Million | -1.432x | -426.07% |
| 2014-12-31 | $-5.68 Million | $-2.50 Million | 0.439x | -92.52% |
| 2013-12-31 | $-610.00K | $-3.58 Million | 5.874x | +125.91% |
| 2012-12-31 | $-595.00K | $-1.55 Million | 2.600x | +385.08% |
| 2011-12-31 | $1.42 Million | $-1.30 Million | -0.912x | +90.47% |
| 2010-12-31 | $135.00K | $-1.29 Million | -9.570x | -617.41% |
| 2009-12-31 | $1.96 Million | $-2.61 Million | -1.334x | +40.95% |
| 2008-12-31 | $2.53 Million | $-5.72 Million | -2.259x | -166.10% |
| 2007-12-31 | $8.76 Million | $-7.43 Million | -0.849x | -124.38% |
| 2006-12-31 | $-2.10 Million | $-7.30 Million | 3.482x | +470.79% |
| 2005-12-31 | $5.38 Million | $-5.05 Million | -0.939x | -15.62% |
| 2004-12-31 | $9.65 Million | $-7.84 Million | -0.812x | -228.14% |
| 2003-12-31 | $-5.38 Million | $-3.41 Million | 0.634x | +180.58% |
| 2002-12-31 | $-8.00 Million | $-1.81 Million | 0.226x | -- |
About Nephros Inc
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella a… Read more